Pharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg (JMU), Am Hubland, 97074 Würzburg, Germany.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
J Med Chem. 2024 Jul 11;67(13):10710-10742. doi: 10.1021/acs.jmedchem.4c00230. Epub 2024 Jun 19.
Upon infection by an intracellular pathogen, host cells activate apoptotic pathways to limit pathogen replication. Consequently, efficient proliferation of the obligate intracellular pathogen , a major cause of trachoma and sexually transmitted diseases, depends on the suppression of host cell apoptosis. secretes deubiquitinase ChlaDUB1 into the host cell, leading among other interactions to the stabilization of antiapoptotic proteins and, thus, suppression of host cell apoptosis. Targeting the bacterial effector protein may, therefore, lead to new therapeutic possibilities. To explore the active site of ChlaDUB1, an iterative cycle of computational docking, synthesis, and enzymatic screening was applied with the aim of lead structure development. Hereby, covalent inhibitors were developed, which show enhanced inhibition with a 22-fold increase in IC values compared to previous work. Comprehensive insights into the binding prerequisites to ChlaDUB1 are provided, establishing the foundation for an additional specific antichlamydial therapy by small molecules.
当宿主细胞受到胞内病原体感染时,会激活凋亡途径以限制病原体的复制。因此,作为沙眼和性传播疾病主要病因的专性胞内病原体的有效增殖依赖于宿主细胞凋亡的抑制。该病原体将去泛素化酶 ChlaDUB1 分泌到宿主细胞中,除其他相互作用外,还导致抗凋亡蛋白的稳定,从而抑制宿主细胞凋亡。因此,针对细菌效应蛋白可能会带来新的治疗可能性。为了探索 ChlaDUB1 的活性位点,应用了计算对接、合成和酶筛选的迭代循环,旨在开发先导结构。由此开发了共价抑制剂,与之前的工作相比,其 IC 值增加了 22 倍,抑制效果增强。为 ChlaDUB1 的结合前提提供了全面的见解,为小分子的额外特异性抗衣原体治疗奠定了基础。